LoginSignup
Grifols logo

Grifols

Stock
Stock
ISIN: ES0171996087
Ticker: GRF
ES0171996087
GRF

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

Grifols has so far distributed $0.0763 in 2026. The next dividend will be paid on 02.07.2027

$0.206

CHART BY

Frequently asked questions

The market capitalization of Grifols is $7.29B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Grifols is 14.14. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Grifols's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.757. EPS indicates the company's profitability on a per-share basis.
Currently, 14 analysts cover Grifols's stock, with a consensus target price of $17.71. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Grifols reported a revenue of $8.45B.
Grifols's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.88B. EBITDA measures the company's overall financial performance.
Grifols has a free cash flow of $933.65M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Grifols employs approximately 25,258 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of Grifols is 278.28M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$7.29B
EPS (TTM) 
$0.757
Free Float 
278.28M
P/E ratio (TTM) 
14.14
Revenue (TTM) 
$8.45B
EBITDA (TTM) 
$1.88B
Free Cashflow (TTM) 
$933.65M

Pricing

1D span
$10.68$11.00
52W span
$9.793$15.09

Analyst Ratings

The price target is $17.71 and the stock is covered by 14 analysts.

Buy

10

Hold

3

Sell

1

Information

Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols i Roig in 1909 and is headquartered in Barcelona, Spain.

Employees
25,258
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

ISIN
ES0171996087
Primary Ticker
GRF

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin